1. Home
  2. KWY vs TLSI Comparison

KWY vs TLSI Comparison

Compare KWY & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kingsway Corporation Common Stock

KWY

Kingsway Corporation Common Stock

HOLD

Current Price

$9.93

Market Cap

283.2M

Sector

Finance

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$3.57

Market Cap

250.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KWY
TLSI
Founded
1989
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.2M
250.0M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
KWY
TLSI
Price
$9.93
$3.57
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $10.40
AVG Volume (30 Days)
34.0K
★ 206.3K
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $134,996,000.00
$45,151,000.00
Revenue This Year
N/A
$17.65
Revenue Next Year
N/A
$40.27
P/E Ratio
★ N/A
N/A
Revenue Growth
23.42
★ 53.41
52 Week Low
$8.41
$2.20
52 Week High
$11.36
$7.95

Technical Indicators

Market Signals
Indicator
KWY
TLSI
Relative Strength Index (RSI) 61.32 30.66
Support Level $9.56 $3.05
Resistance Level $10.30 $3.68
Average True Range (ATR) 0.26 0.21
MACD 0.07 -0.02
Stochastic Oscillator 100.00 7.07

Price Performance

Historical Comparison
KWY
TLSI

About KWY Kingsway Corporation Common Stock

Kingsway Corp is a U.S.-based company employing the Search Fund model to acquire and build great businesses. The company owns and operates a collection of B2B and B2C services companies that are asset-light, growing, profitable, and that have recurring revenues. It seeks to compound long-term shareholder value on a per share basis via its decentralized management model, its talented team of operators, and its tax-advantaged corporate structure.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: